复星医药:复宏汉霖是本集团重要的抗体技术平台,专注于生物制药的创新研发

证星董秘互动
27 Jan

证券之星消息,复星医药(600196)01月27日在投资者关系平台上答复投资者关心的问题。投资者:公司私有化复宏汉霖失败,是否考虑直接在二级市场增持复宏的股权?复星医药董秘:投资者您好!复宏汉霖是本集团重要的抗体技术平台,专注于生物制药的创新研发,持续深化境内市场,并积极拓展境外市场,致力于高质量发展。截至2025年1月22日,复星医药(通过控股子公司)合计持有复宏汉霖59.56%的股权。后续公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10